Trials / Approved For Marketing
Approved For MarketingNCT06628713
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
On Demand Treatment of Angioedema Attacks in Adolescent and Adult Post-Trial and Naive Patients 12 Years and Older With Hereditary Angioedema (HAE) Type I or II With Sebetralstat
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- KalVista Pharmaceuticals, Ltd. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Type I or II Hereditary Angioedema (HAE) adolescent and adult post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sebetralstat | Oral Plasma Kallikrein Inhibator |
Timeline
- First posted
- 2024-10-08
- Last updated
- 2025-08-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06628713. Inclusion in this directory is not an endorsement.